Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

Purpose: Glioblastoma is refractory to conventional therapies. The bromodomain and extraterminal domain (BET) proteins are epigenetic readers that selectively bind to acetylated lysine residues on histone tails. These proteins recently emerged as important therapeutic targets in NUT midline carcinoma and several types of hematopoietic cancers. In this study, the therapeutic potential of a novel BET bromodomain inhibitor, JQ1, was assessed in a panel of genetically heterogeneous glioblastoma samples. Experimental Design: The antineoplastic effects of JQ1 were shown using ex vivo cultures derived from primary glioblastoma xenograft lines and surgical specimens of different genetic background. The in vivo efficacy was assessed in orthotopic glioblastoma tumors. Results: We showed that JQ1 induced marked G1 cell-cycle arrest and apoptosis, which was phenocopied by knockdown of individual BET family members. JQ1 treatment resulted in significant changes in expression of genes that play important roles in glioblastoma such as c-Myc, p21CIP1/WAF1, hTERT, Bcl-2, and Bcl-xL. Unlike the observations in some hematopoietic cancer cell lines, exogenous c-Myc did not significantly protect glioblastoma cells against JQ1. In contrast, ectopically expressed Bcl-xL partially rescued cells from JQ1-induced apoptosis, and knockdown of p21CIP1/WAF1 attenuated JQ1-induced cell-cycle arrest. Cells genetically engineered for Akt hyperactivation or p53/Rb inactivation did not compromise JQ1 efficacy, suggesting that these frequently mutated signaling pathways may not confer resistance to JQ1. Furthermore, JQ1 significantly repressed growth of orthotopic glioblastoma tumors. Conclusion: Our results suggest potentially broad therapeutic use of BET bromodomain inhibitors for treating genetically diverse glioblastoma tumors. Clin Cancer Res; 19(7); 1748–59. ©2013 AACR.

[1]  Julio E. Agno,et al.  Small-Molecule Inhibition of BRDT for Male Contraception , 2012, Cell.

[2]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[3]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[4]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[5]  P. Bamborough,et al.  Discovery and characterization of small molecule inhibitors of the BET family bromodomains. , 2011, Journal of medicinal chemistry.

[6]  S. Hung,et al.  Knockdown of p21Cip1/Waf1 enhances proliferation, the expression of stemness markers, and osteogenic potential in human mesenchymal stem cells , 2011, Aging cell.

[7]  H. Varmus,et al.  Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins , 2012, Proceedings of the National Academy of Sciences.

[8]  Santosh Kesari,et al.  Malignant gliomas in adults. , 2008, The New England journal of medicine.

[9]  Hui Wang,et al.  c-Myc Is Required for Maintenance of Glioma Cancer Stem Cells , 2008, PloS one.

[10]  S. Sathornsumetee,et al.  Designer Therapies for Glioblastoma Multiforme , 2008, Annals of the New York Academy of Sciences.

[11]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[12]  Wei Zhang,et al.  Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. , 2013, Cancer research.

[13]  R. Beddington,et al.  Growth and Early Postimplantation Defects in Mice Deficient for the Bromodomain-Containing Protein Brd4 , 2002, Molecular and Cellular Biology.

[14]  R. Henkelman,et al.  Identification of human brain tumour initiating cells , 2004, Nature.

[15]  C. Harley,et al.  Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition , 2010, Clinical Cancer Research.

[16]  Gerald C. Chu,et al.  Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. , 2008, Cold Spring Harbor symposia on quantitative biology.

[17]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[18]  A. Khayat,et al.  c-MYC amplification and expression in astrocytic tumors , 2008, Acta Neuropathologica.

[19]  Chi V Dang,et al.  MYC on the Path to Cancer , 2012, Cell.

[20]  B. Sullenger,et al.  Notch Promotes Radioresistance of Glioma Stem Cells , 2009, Stem cells.

[21]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[22]  J. Aster,et al.  BRD–NUT oncoproteins: a family of closely related nuclear proteins that block epithelial differentiation and maintain the growth of carcinoma cells , 2008, Oncogene.

[23]  J. Sarkaria,et al.  p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. , 2012, Neuro-oncology.

[24]  A. Fisher,et al.  Epigenetic signatures of stem-cell identity , 2007, Nature Reviews Genetics.

[25]  Tzong-Shiue Yu,et al.  A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .

[26]  J. Brady,et al.  The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. , 2005, Molecular cell.

[27]  P. Sandy,et al.  Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.

[28]  J. Sarkaria,et al.  Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery , 2011, Current protocols in pharmacology.

[29]  Qiang Zhou,et al.  Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. , 2005, Molecular cell.

[30]  C. Rice,et al.  Suppression of inflammation by a synthetic histone mimic , 2010, Nature.

[31]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[32]  Stephen L. Abrams,et al.  Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways , 2011, Journal of cellular physiology.

[33]  Stefan Knapp,et al.  Bromodomains as therapeutic targets , 2011, Expert Reviews in Molecular Medicine.

[34]  A. Belkina,et al.  BET domain co-regulators in obesity, inflammation and cancer , 2012, Nature Reviews Cancer.

[35]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[36]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[37]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[38]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[39]  M. Prados,et al.  Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. , 2010, Cancer research.

[40]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[41]  C. James,et al.  Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.

[42]  W. Cavenee,et al.  Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.

[43]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[44]  Yuri Kotliarov,et al.  Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. , 2006, Cancer cell.

[45]  S. Robson,et al.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia , 2011, Nature.

[46]  Tony Kouzarides,et al.  Targeting epigenetic readers in cancer. , 2012, The New England journal of medicine.

[47]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[48]  Xiangyuan Wang,et al.  Double bromodomain‐containing gene Brd2 is essential for embryonic development in mouse , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[49]  B. N. Devaiah,et al.  BRD4 is an atypical kinase that phosphorylates Serine2 of the RNA Polymerase II carboxy-terminal domain , 2012, Proceedings of the National Academy of Sciences.